

ProviderAlert

To: Select Health Providers

Date: July 31, 2026

Subject: Pharmacy Update: Humira® is Now Non-Preferred

Summary: Effective **August 1, 2026**, **Humira®** will become non-preferred status on the South Carolina Healthy Connections Medicaid Single Preferred Drug List (sPDL).

South Carolina Healthy Connections Medicaid periodically updates preferred medications under the [South Carolina Single Preferred Drug List \(sPDL\)](#). Beginning August 1, 2026, preferred **adalimumab biosimilars** should be prescribed when clinically appropriate. This will help support timely pharmacy processing and continued member access to appropriate medications.

What you need to know:

- **Adalimumab biosimilars** are preferred products on the South Carolina Medicaid sPDL.
- Humira® (adalimumab) is now non-preferred on the South Carolina Medicaid sPDL.

Preferred Products

Product	Status
Adalimumab-adaz Injection (unbranded Hyrimoz®)	Preferred
Hadlima® Injection (adalimumab-bwwd)	Preferred

Non-Preferred Products

Product	Status
Humira® (adalimumab)	Non-Preferred

How providers can support members:

Your partnership helps members continue treatment with fewer interruptions. To support this transition, providers are encouraged to take the following steps:

- **Review** members currently prescribed Humira® (adalimumab).
- **Prescribe** the preferred equivalent, when clinically appropriate.
- **Let members know** the medication may look different, while continuing to provide the same intended course of treatment.

Thank you for your continued partnership in helping Select Health members receive safe, coordinated, and timely access to appropriate medications.

For the most current sPDL please visit the South Carolina Healthy Connections Medicaid website at <https://southcarolina.fhsc.com/providers/pdl.asp>.